share_log

Jacobson Pharma's (HKG:2633) Profits Appear To Have Quality Issues

Simply Wall St ·  Dec 21, 2023 17:52

Jacobson Pharma Corporation Limited's (HKG:2633) robust recent earnings didn't do much to move the stock. However the statutory profit number doesn't tell the whole story, and we have found some factors which might be of concern to shareholders.

Check out our latest analysis for Jacobson Pharma

earnings-and-revenue-history
SEHK:2633 Earnings and Revenue History December 21st 2023

How Do Unusual Items Influence Profit?

For anyone who wants to understand Jacobson Pharma's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from HK$48m worth of unusual items. While we like to see profit increases, we tend to be a little more cautious when unusual items have made a big contribution. We ran the numbers on most publicly listed companies worldwide, and it's very common for unusual items to be once-off in nature. Which is hardly surprising, given the name. If Jacobson Pharma doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Jacobson Pharma.

Our Take On Jacobson Pharma's Profit Performance

Arguably, Jacobson Pharma's statutory earnings have been distorted by unusual items boosting profit. Therefore, it seems possible to us that Jacobson Pharma's true underlying earnings power is actually less than its statutory profit. But at least holders can take some solace from the 30% per annum growth in EPS for the last three. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. If you'd like to know more about Jacobson Pharma as a business, it's important to be aware of any risks it's facing. For example, we've found that Jacobson Pharma has 2 warning signs (1 is a bit concerning!) that deserve your attention before going any further with your analysis.

This note has only looked at a single factor that sheds light on the nature of Jacobson Pharma's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment